Wire · regulatory
Entropy Neurodynamics advances TRP-8803 with 72 patient psychedelic therapy trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 August 2026 · Fusion42 review
Entropy Neurodynamics has received ethical approval to begin a Phase 1b/2a basket trial for TRP-8803, an intravenous psilocin formulation, enrolling 72 patients across eight neuropsychiatric disorders. The multi-indication study aims to accelerate evaluation of treatment-resistant depression, anxiety, PTSD, and other disorders using precise dosing control and psychedelic-assisted psychotherapy.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You now have a route to test psychedelic therapies across multiple disorders simultaneously in Australia, unlocking faster insights on where your drug can succeed. Prepare to engage clinical sites and therapy experts early to take full advantage of this streamlined trial design.
◆ Coverage
1 source · 4 Aug 2026
◆ Related on Wire
◆ Topics